PMID- 35722557
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 13
DP  - 2022
TI  - A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the 
      Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder.
PG  - 873693
LID - 10.3389/fpsyt.2022.873693 [doi]
LID - 873693
AB  - INTRODUCTION: Due to the complexity of symptoms in major depressive disorder 
      (MDD), the majority of depression scales fall short of accurately assessing a 
      patient's progress. When selecting the most appropriate antidepressant treatment 
      in MDD, a multidimensional scale such as the Hamilton Depression Rating scale 
      (HAM-D) may provide clinicians with more information especially when coupled with 
      unidimensional analysis of some key factors such as depressed mood, altered 
      sleep, psychic and somatic anxiety and suicidal ideation etc. METHODS: HAM-D 
      measurements were carried out in patients with MDD when treated with two 
      different therapeutic interventions. The prespecified primary efficacy variables 
      for the study were changes in score from baseline to the end of the 12 weeks on 
      HAM-D scale (i.e., </= 8 or >/=50% response). The study involved three assessment 
      points (baseline, 6 weeks and 12 weeks). RESULTS: Evaluation of both the absolute 
      HAM-D scores and four factors derived from the HAM-D (depressed mood, sleep, 
      psychic and somatic anxiety and suicidal ideation) revealed that the latter 
      showed a greater promise in gauging the anti-depressant responses. CONCLUSION: 
      The study confirms the assumption that while both drugs may improve several items 
      on the HAM-D scale, the overall protocol may fall short of addressing the 
      symptoms diversity in MDD and thus the analysis of factor (s) in question might 
      be more relevant and meaningful.
CI  - Copyright (c) 2022 Asghar, Tabasam, Althobaiti, Adnan Ashour, Aleid, Ibrahim Khalaf 
      and Aldhyani.
FAU - Asghar, Junaid
AU  - Asghar J
AD  - Faculty of Pharmacy, Gomal University, D. I. Khan, Pakistan.
FAU - Tabasam, Madiha
AU  - Tabasam M
AD  - Faculty of Pharmacy, Gomal University, D. I. Khan, Pakistan.
FAU - Althobaiti, Maha M
AU  - Althobaiti MM
AD  - Department of Computer Science, Taif University, Taif, Saudi Arabia.
FAU - Adnan Ashour, Amal
AU  - Adnan Ashour A
AD  - Department of Oral & Maxillofacial Surgery, Taif University, Taif, Saudi Arabia.
FAU - Aleid, Mohammed A
AU  - Aleid MA
AD  - College of Education, King Faisal University, Al-Ahsa, Saudi Arabia.
FAU - Ibrahim Khalaf, Osamah
AU  - Ibrahim Khalaf O
AD  - Al-Nahrain Nanorenewable Energy Research Center, Al-Nahrain University, Baghdad, 
      Iraq.
FAU - Aldhyani, Theyazn H H
AU  - Aldhyani THH
AD  - Applied College in Abqaiq, King Faisal University, Al-Ahsa, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20220527
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC9197773
OTO - NOTNLM
OT  - HAM-D
OT  - antidepressant
OT  - escitalopram
OT  - major depressive disorder
OT  - nortriptyline
OT  - remission
OT  - response
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/21 06:00
MHDA- 2022/06/21 06:01
PMCR- 2022/05/27
CRDT- 2022/06/20 04:09
PHST- 2022/02/11 00:00 [received]
PHST- 2022/05/02 00:00 [accepted]
PHST- 2022/06/20 04:09 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/21 06:01 [medline]
PHST- 2022/05/27 00:00 [pmc-release]
AID - 10.3389/fpsyt.2022.873693 [doi]
PST - epublish
SO  - Front Psychiatry. 2022 May 27;13:873693. doi: 10.3389/fpsyt.2022.873693. 
      eCollection 2022.